April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
IOP Parameters and Visual Field Progression in Patients With Treated Glaucoma
V. V. Juthani; C. G. de Moraes; C. A. Liebmann; C. C. Teng; C. Tello; R. Ritch; J. M. Liebmann
Author Affiliations & Notes
  • V. V. Juthani
    Ophthalmology, New York University, New York, New York
  • C. G. de Moraes
    Ophthalmology, New York Eye & Ear Infirmary and NYU Medical Center, New York, New York
  • C. A. Liebmann
    Ophthalmology, New York Eye and Ear Infirmary, New York, New York
  • C. C. Teng
    Ophthalmology, New York Eye and Ear Infirmary and New York Medical College, New York, New York
  • C. Tello
    Ophthalmology, New York Eye and Ear Infirmary and New York Medical College, New York, New York
  • R. Ritch
    Ophthalmology, New York Eye and Ear Infirmary and New York Medical College, New York, New York
  • J. M. Liebmann
    Ophthalmology, New York Eye and Ear Infirmary and NYU Medical Center, New York, New York
  • Footnotes
    Commercial Relationships  V.V. Juthani, None; C.G. de Moraes, None; C.A. Liebmann, None; C.C. Teng, None; C. Tello, Diopsys, Inc., F; Alcon Laboratories, Inc., R; Allergan, Inc., R; R. Ritch, Diopsys, Inc., F; Heidelberg Engineering, GmBH., F; Topcon, Inc., F; Alcon Laboratories, Inc., C; Allergan, Inc., C; Danube Pharmaceuticals, Inc., C; Carl Zeiss Meditec, Inc., F; Pfizer Ophthalmics, Inc., C; J.M. Liebmann, Carl Zeiss Meditec, Inc., F; Diopsys, Inc., F; Heidelberg Engineering, GmbH., F; Topcon Medical Systems, Inc., F; Optovue, Inc., F; Alcon Laboratories, Inc., C; Allergan, Inc., C; Diopsys, Inc., C; Optovue, Inc., C; Pfizer Inc., C; Topcon Medical Systems, Inc., C.
  • Footnotes
    Support  Supported in part by the Eye Bank for Sight Restoration, New York, NY, and the Corrine Graber Research Fund of the New York Glaucoma Research Institute, New York, NY
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 3496. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      IOP Parameters and Visual Field Progression in Patients With Treated Glaucoma
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      V. V. Juthani, C. G. de Moraes, C. A. Liebmann, C. C. Teng, C. Tello, R. Ritch, J. M. Liebmann; IOP Parameters and Visual Field Progression in Patients With Treated Glaucoma. Invest. Ophthalmol. Vis. Sci. 2010;51(13):3496.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : To determine which IOP parameter correlates most highly with visual field (VF) progression in treated glaucoma patients.

Methods: : The charts of all patients seen in a glaucoma referral practice between 1999 and 2009 were reviewed. Only eyes with >8 SITA Standard 24-2 VF tests with baseline glaucomatous VF damage were included. Mean follow-up IOP (mmHg), peak IOP, IOP fluctuation (standard deviation), age, CCT, and baseline mean deviation (MD) for each patient were recorded. Automated pointwise linear regression analysis determined global and localized rates (dB/yr) of change. Progression was defined when 2 or more adjacent test locations in the same hemifield showed a threshold sensitivity decline at a rate of >1.0 dB/year with p<0.01.

Results: : 587 eyes (587 patients; mean age, 64.9±13.0 yrs; mean number of VF tests, 11.1±3.0; mean follow-up, 6.4±1.7 yrs) were included. 169 (28.8%) eyes progressed. Progressing eyes had thinner corneas (533±38 vs. 544±36 µm, p=0.001), higher mean IOP (15.9±2.82 vs. 14.9±3.2, p<0.001), higher peak IOP (21.4±4.5 vs. 19.3±4.4, p<0.001), and greater IOP fluctuation (3.0±1.6 vs. 2.4±1.3, p<0.001) than non-progressing eyes. Global rates of change of progressing eyes were faster than non-progressing eyes (-1.1±0.89 vs. -0.2±0.5 dB/yr, p<0.001). There was moderate to strong correlation among all IOP parameters (all p<0.01). Peak IOP showed the best association with VF progression (AUROC for Peak IOP, 0.636±0.026; 0.618±0.026 for IOP fluctuation; 0.587±0.026 for mean IOP).

Conclusions: : Trend analysis confirms the important roles of age, CCT, and IOP on VF progression in treated glaucoma. Peak IOP is the most important IOP parameter and should be minimized in these eyes.

Keywords: intraocular pressure • visual fields 
© 2010, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2024 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept